Page 12«..11121314..2030..»

You are currently browsing the Nano Medicine category

Global Digital Pathology Market to Expand with Increasing Relevance of Biological Specimens – TMR BLOG

§ May 6th, 2020 § Filed under Nano Medicine Comments Off on Global Digital Pathology Market to Expand with Increasing Relevance of Biological Specimens – TMR BLOG

The presence of a growth-oriented healthcare sector has opened new avenues for expansion across the global digital pathology market. The use of data and information across the healthcare industry has created new pathways for the domain of diagnostics. Pathological systems and tests play an important role in diagnosing diseases. Besides, these tests can also be used to study blood and urinary samples of humans as well as animals. In this scenario, it is safe to expect that the healthcare industry would increase its bar of investment in the field of pathology. This factor, coupled with the advent of digital transformation in healthcare, shall given an impetus to market growth and maturity.

In this blog by Transparency Market Research (TMR), analysts elucidate credible information and trends pertaining to the growth of the global digital pathology market.

1. Use of Data Generated from Digitized Specimens

The use of digital pathology has opened new avenues to understand virtual microscopy. The study of microscopic samples has become possible with the advent of new-age technologies within pathology. Besides, the unprecedented need for whole-slide imaging across research labs has given an impetus to the popularity of digital pathology. Whole-slide imaging is an important application in diagnostic medicine, and the former is accomplished with the help of digital pathology.

To Get an Exhaustive Overview about the Competition in Digital Pathology Market, Request for a Report Brochure at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1540

2. Disease Prediction as an Emerging Component of Modern Medicine

The need for economical diagnosis and prognosis cannot be undermined in the current times. Furthermore, disease prediction also follows from efficient use of diagnostic lines. The aforementioned factors have played a decisive role in driving sales across the global digital pathology market. Moreover, the use of digital pathology in accessing information about past specimens has also aided market growth and maturity. Over the course of the next decade, the total volume of revenues within the global digital pathology market shall multiply.

Like Loading...

Continue reading here:
Global Digital Pathology Market to Expand with Increasing Relevance of Biological Specimens - TMR BLOG

Read the Rest...

Hospital-acquired Disease Testing Market Report Outlining the Current State of the Market by 2020-2027 Along with Key Players Abbott Laboratories,…

§ May 6th, 2020 § Filed under Nano Medicine Comments Off on Hospital-acquired Disease Testing Market Report Outlining the Current State of the Market by 2020-2027 Along with Key Players Abbott Laboratories,…

Hospital-acquired Disease Testing Market is a comprehensive report on the global market provides in-depth insight into the industry covering all the important parameters and analyzes that provide qualitative insight into the factors that affect Global Hospital-acquired Disease Testing Market growth. Includes all regions and countries in the world that show regional development status including market size.

Global Hospital-acquired Disease Testing Market research report has published by HealthCare Intelligence Markets and it is an effective data source for the readers. It offers widespread information on the Global Hospital-acquired Disease Testing Market. The purpose of this study is to define the overview of the global market with respect to market size, shares, sales patterns, and pricing structures. Primary and secondary research refers to collect the desired data of the target market.

Ask for Sample Copy of This Report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=141010

Top Key Players Included in This Report:

Abbott Laboratories, Becton and Dickenson, BioMerieux, Roche Diagnostics, Akers Biosciences, Alere

The research objectives of this report are as follows:

Get Discount on This Report: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=141010

The report also summarized the high revenue generated with market facts and figures across regions such as North America, Japan, Europe, Asia, and India. We focus on the key issues needed to have a positive impact on the market, such as policy, international trade, and speculation, and supply-demand in the Global Hospital-acquired Disease Testing Market.

This market research report on the Global Hospital-acquired Disease Testing Market is a comprehensive study of industry-specific frameworks, industry-strength drivers, and manacles. Over the next seven years, we will provide market forecasts for the future. The study also provides markets for sectors such as end-users, industries, and size.

The report also covers in-depth explanations, competitive scenarios, and a broad product portfolio with a broad product portfolio of key players in Global Hospital-acquired Disease Testing Market and SWOT analysis adopted by competitors. This report provides Porter analysis, PESTEL analysis, and market appeal to help you better understand macro and microscopic market scenarios.

If You Have Any Query, Ask Our Experts: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=141010

Table of Contents:

Chapter 1: Global Hospital-acquired Disease Testing Market Overview Chapter 2: Global Economic Impact on Industry Chapter 3: Production, Revenue (Value) by Region Chapter 4: Supply (Production), Consumption, Export, Import by Regions Chapter 5: Production, Revenue (Value), Price Trend by Type Chapter 6: Global Hospital-acquired Disease Testing Market Analysis by Application Chapter 7: Manufacturing Cost Analysis Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 9: Marketing Strategy Analysis, Distributors/Traders Chapter 10: Market Effect Factors Analysis Chapter 11: Global Hospital-acquired Disease Testing Market Forecast

Hospital Acquired Pneumonia Drugs Global Market 2020 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. The Market report offers noteworthy data regarding industrys growth parameters, the current

View post:
Hospital-acquired Disease Testing Market Report Outlining the Current State of the Market by 2020-2027 Along with Key Players Abbott Laboratories,...

Read the Rest...

Electroceuticals/Bioelectric Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County Courier

§ May 6th, 2020 § Filed under Nano Medicine Comments Off on Electroceuticals/Bioelectric Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County Courier

Electrocore

Electroceuticals/Bioelectric Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=16442&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Electroceuticals/Bioelectric Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Electroceuticals/Bioelectric Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electroceuticals/Bioelectric Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Electroceuticals/Bioelectric Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Electroceuticals/Bioelectric Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Electroceuticals/Bioelectric Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/electroceuticals-bioelectric-medicine-market/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: sales@verifiedmarketresearch.com

Tags: Electroceuticals/Bioelectric Medicine Market Size, Electroceuticals/Bioelectric Medicine Market Trends, Electroceuticals/Bioelectric Medicine Market Forecast, Electroceuticals/Bioelectric Medicine Market Growth, Electroceuticals/Bioelectric Medicine Market Analysis

See the original post:
Electroceuticals/Bioelectric Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier

Read the Rest...

NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA – Business Wire

§ May 6th, 2020 § Filed under Nano Medicine Comments Off on NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA – Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the protocol for the first trial from its clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) has been designated as safe to proceed by the US Food and Drug Administration (FDA). The trial was co-developed with Nanobiotix and MD Anderson is the sponsor and executor of the trial.

The investigational new drug application (IND), covers a phase I study evaluating the safety and feasibility of NBTXR3 activated by radiation therapy for patients with locally advanced (LAPC) or borderline resectable (BRPC) cases of pancreatic ductal adenocarcinoma (PDAC). This trial is the first to evaluate NBTXR3 activated by radiation therapy in pancreatic cancer.

Significant Unmet Needs and Opportunity in Pancreatic Cancer

Pancreatic cancer is a rare, deadly disease. Given that surgery with R0 resection (i.e. macroscopically complete tumor removal with negative microscopic surgical margins) remains the only hope for long-term survival, clinical trials have investigated various neoadjuvant strategieswherein patients receive anti-cancer drugs or radiation prior to surgeryto increase the surgery-eligible population while also increasing the R0 resection rate.

In support of the rationale for neoadjuvant therapy, a retrospective analysis demonstrated a near doubling in overall survival (OS) in PDAC patients who underwent surgery, which was attributed, at least in part, to the increased proportion of BRPC patients who became eligible for surgery as a result of neoadjuvant intervention. Importantly, there are also select cases of LAPC patients being considered for surgical resection based on their response to therapy. Given the poor prognosis of PDAC, therapeutic regimens able to increase the proportion of BRPC and LAPC patients eligible for surgery could improve survival outcomes in this population with unmet need.

A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with PADC

The MD Anderson trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D); and (ii) expansion at RP2D.

The patient population will include adults (age 18 years) with BRPC or LAPC that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D. Up to 24 subjects will be enrolled, including a maximum of 12 subjects with LAPC for the dose-finding part. Twelve additional subjects with either LAPC or BRPC will be enrolled for the RP2D expansion. The planned enrollment period is 18 months. The first patient should be injected the summer of 2020.

The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, pancreas, and breast cancers.

NBTXR3 is actively being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory IND process to commence a phase III clinical trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. Pursuant to an effective IND, the Company has launched a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. The company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, lung, gastrointestinal and advanced cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Continue reading here:
NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA - Business Wire

Read the Rest...

Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024…

§ May 5th, 2020 § Filed under Nano Medicine Comments Off on Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024…

Transportation restrictions and stringent government policies are causing a downturn in the growth scale of the Nanomedicine market amidst the COVID-19 (Coronavirus) lockdown period. Hence, analysts at Market Research Reports Search Engine (MRRSE) have collated a research study that provides an in-depth outlook on Coronavirus and how the novel virus can leave long-term effects in trade practices post lockdown period in the Nanomedicine market.

Why Choose MRRSE?

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

The report on the global Nanomedicine market published by MRRSE provides a clear understanding of the flight of the Nanomedicine market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Nanomedicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Nanomedicine market are analyzed in the report.

The study reveals that the global Nanomedicine market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Nanomedicine market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Key Takeaways of the Report:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/3117?source=atm

Nanomedicine Market Segmentation

The presented study throws light on the current and future prospects of the Nanomedicine market in various geographies such as:

The report highlights the product adoption pattern of various products in the Nanomedicine market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Go here to see the original:
Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024...

Read the Rest...

Does the dusk of old-school antibiotics mean the dawn of antimicrobial nanomaterials? – Advanced Science News

§ May 5th, 2020 § Filed under Nano Medicine Comments Off on Does the dusk of old-school antibiotics mean the dawn of antimicrobial nanomaterials? – Advanced Science News

Share

Share

Email

The research and development of antibiotics has been intense since their discovery in the early part of the past century.

However, in the last decade, there has been a dramatic shift in their effectiveness. More and more bacterial strains have developed resistance to antibiotics, and these resistant microorganisms are able to withstand the activity of commonly used antimicrobial drugs in a way that standard treatment becomes ineffective and infections persist. This increases the risk of their spread, which is clearly seen in clinical practice supported by World Health Organization annual reports.

The development of resistant strains is a natural phenomenon that occurs through selective pressure on the population of microorganisms. It is no surprise, then, that there is a general increase in the number of resistant microorganisms all around the world, although specific patterns vary considerably across countries.

Nanomaterials include a variable range of colloidal nanoparticles not only in terms of chemical composition but also in terms of shape and size, which significantly affect the desired properties their effect and biocompatibility, in particular. These properties can be customized during or after the preparation of nanoparticles according to the intended application.

Basic research includes the study of the relationship between morphology and physico-chemical and biological properties of nanomaterials, which form the theoretical basis for the design and synthesis of new generations of nanomaterials having specific applications in medicine. Due to their dimensions, nanoparticles are getting close to their target biological entities.

Current research in the field of nanomedicine focuses primarily on the rational transport of diagnostic and therapeutic agents to eliminate side effects and precisely target the desired location in the organism. Applications are not only available in human medicine but also in veterinary medicine and agriculture.

Dr. Smerkova and her colleagues from Mendel University in Brno, Czech Republic, have recently discussed current trends in the synthesis, development, and applications of advanced nanomaterials as alternatives to antibiotics. Although the active targeting of pathogens is a relatively emerging area, it has the potential to provide many benefits, including the improvement of therapeutic outcomes due to selectively targeting pathogens while sparing the human microbiome.

These aspects are inevitably associated with decreased side effects and reduction of socio-economical losses, and thus represent the golden grail of antibacterial treatment.

Besides these primary impacts, the fight against bacterial biofilm formation represents an important challenge for targeting strategies. The nanoparticles unique physicochemical properties allow them enhanced penetration through biofilm and to kill shielded bacteria by direct contact with intrinsic antibacterial nanomaterial or by antimicrobials delivery, explained Dr. Smerkova.

The targeting of intracellular pathogens surviving in hijacked macrophages is another special assignment of antimicrobial nanoparticles or nanocarriers loaded with antibiotics. On the other hand, due to their multicomponent and complex nature, actively targeted nanoparticles require a comprehensive understanding of their in-vivo stability, possible off-target effects, or loss of targeting ability due to protein corona formation and intracellular and organismal fate.

Dr. Smerkova also stated: For further acceleration of the development in the field of efficient targeting ligands for antibacterial nanoparticles, detailed knowledge of pathogen-specific surface structures needs to be gathered. In addition, high-throughput methods capable of screening for similarities with surface structures of common or uncommon members of the microbiome to achieve maximal selectivity are of an utmost interest.

Since science is experiencing the advent of superfast computational units capable of such screenings, it can be expected that virtual screening software will pave the way for novel targeting ligands based on a broad spectrum of various biomolecules. This would be a major leap forward and towards ligands that help generate an inexhaustible spectrum of novel antibacterial nanomaterials that could be used to combat the global threat posed by antibiotic-resistant bacteria.

Article written by Kristyna Smerkova, Kristyna Dolezelikova, Lucie Bozdechova, Zbynek Heger, Ludek Zurek, and Vojtech Adam

Reference: Kristyna Smerkova et al. Nanomaterials with active targeting as advanced antimicrobials. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1636

First human trial finds CRISPR-edited cells for cancer treatment are safe and durable

Encoding molecular interactions: Advancing drug design

Pioneers in Science: Sir Frederick Banting

Treating Cancer Using Lessons from NASA

Read the original here:
Does the dusk of old-school antibiotics mean the dawn of antimicrobial nanomaterials? - Advanced Science News

Read the Rest...

Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept – BioSpace

§ May 5th, 2020 § Filed under Nano Medicine Comments Off on Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept – BioSpace

TORONTO, May 5, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) -Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. ("Saugatuck"). Portage Biotech Inc. holds an 70% equity interest in Saugatuck.

Portage is pleased to announce that initial proof of concept of the nanolipogel ("NLG") formulation has been achieved with the initial investment. This has triggered the next tranche of capital infusion of $700,000 USD. Saugatuck has been able to formulate a proprietary PD1 aptamer in the NLG formulation and have shown the formulation properly modulates PD1 signaling. In non clinical in vivo experiments, the NLG-PD1 performed favorably compared to a mouse PD1 antibody. The additional founding will support exploration of multiple PD1 based co-formulations with small molecules and other DNA aptamers.

Separately, this work has triggered a license from D5 pharma to create additional proprietary DNA aptamers for immune-oncology targets. This license sits in another Portage company, Oncomer. Oncomer supplies Saugatuck with aptamers to be formulated in the NLG platform.

Dr. Ian Walters, CEO of Saugatuck and Portage commented, "Most cancers are treated with multiple agents. Our co-formulation platform leverages the ability to modulate several pathways in a single product and direct its distribution to tumors. I am excited to begin testing our next wave of combinations in animal models and prioritizing our first clinical candidate."

About Saugatuck Therapeutics Ltd.

NLG technology, invented in the lab of Dr. Tarek Fahmy at Yale University and commercially developed by our joint venture partner, Immunova,allows different combinations of drugs to be encapsulated in a single nanomedicine and delivered selectively to the tumor microenvironment, thus potentially minimizing systemic side-effects. Saugatuck which has acquired an exclusive license from Yale University via Immunova for use of the NLG platform for delivering DNA aptamers and certain aptamer-based combination products. Immunova is developing a pipeline of NLG drugs focused on cytokine and other immune modulating drugs.

About Portage Biotech Inc.

Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of commercially-informed development plans. Our portfolio encompasses nine subsidiary companies whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.

About D5pharma:

D5Pharma is an early stage biotech based out of Sunnybrook Research Institute in Toronto that identifies novel DNA scaffold molecules for therapeutic development in oncology and inflammatory diseases. Its most advanced compound in development is an anti-CD200R1 aptamer for the treatment of asthma that was developed out of the laboratory of Dr. Jean Gariepy. This new partnership with Oncomer will enable D5 to build out its oncology portfolio by delivering aptamers in new and more effective ways.

Forward-Looking Statements

This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

View original content:http://www.prnewswire.com/news-releases/portage-makes-an-additional-investment-in-saugatuck-therapeutics-after-achieving-proof-of-concept-301052356.html

SOURCE Portage Biotech Inc.

Continued here:
Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept - BioSpace

Read the Rest...

Kolkata institute claims cure for Covid-19, but drug will take two years to hit market – The Indian Express

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Kolkata institute claims cure for Covid-19, but drug will take two years to hit market – The Indian Express

Written by Esha Roy | New Delhi | Published: May 1, 2020 9:06:32 am The nanomedicine is made by combining the nanoparticles extracted from manganese salt with citrus extract, like from lemon. (Representational)

Scientists at the S.N.Bose National Centre for Basic Sciences (SNBNCBS) in Kolkata have now developed a nanomedicine to counter a number of diseases, and say that the medicine can also be an effective cure for the Covid-19 virus. The medicine, which is developed using nanotechnology, and also involves the use of nanoparticles as its component, has already been tested successfully on animals and now awaits human trials. But for it to be used against the Covid-19 virus, the institute will have to acquire a strain of the virus and then begin testing on animals afresh a process that is likely to take anywhere between one and a half to two years.

Dr.Samir Pal, a professor at the institutes Department of Chemical, Biological and Macromolecular Sciences, and a former professor at the California Institute of Technology, who has spearheaded the development of the nanomedicine says that disease is here to stay.

It is important that the nanomedicine be tested to see its efficacy with regards to the Covid-19 virus even if it does take two years to reach the market. Even if the pandemic does get over soon, the disease is here to stay and we will need a cure. And a pandemic may resurface in the near future as well, he said.

The nanomedicine is made by combining the nanoparticles extracted from manganese salt with citrus extract, like from lemon. The nanomedicine is far more effective than normal drugs, says Dr.Pal, because it has the ability to go past RNA/DNA and other barriers due to the nature of its size.

The medicine releases Reactive Oxygen Species into cells, which act like an alarm system, prompting cells to become aware of danger that a particular virus or bacteria or antigen poses to the cell and the human body. The cell will start attacking the virus. If the nanomedicine is introduced in slightly higher quantity, then instead of just prompting the call to fight the disease, the ROS can directly kill the disease. The medicine has a high immune-modulatory effect, adds Dr.Pal.

The research, that the Institute has undertaken for the past three years, has completed its animal trials and proved its efficacy against a number of diseases including jaundice, neonatal jaundice, chronic kidney diseases and a number of neural problems. The institute has applied to the DCGI for permission to begin human trials for the nanomedicine. So far, the nanomedicine has been developed as an injection, but Dr.Pal suggests that the medicine be adjusted to be used with a nebulizer in the context of the Coronavirus.

The artificially made nanomedicine was found to be important to maintain a balance of reduction and oxidation processes (Redox) in our bodys tissues. Redox reactions in cells add or remove oxygen, and are essential for many processes such as generating energy in cells. The redox reactions can also create the Reactive Oxygen Species (ROS), which can instantly oxidize lipids (fat), proteins, and nucleic acids, accelerating the ageing process. Our immune cells naturally produce ROS or generate oxidative stress to kill viruses or bacteria and infected cells in our body. The nanomedicine simply aims at a controlled-increase of ROS or oxidative stress aids our immune cells to perform their natural functions more efficiently.

The animals trials, say Dr.Pal, have shown that the nanomedicine can bring down bilirubin levels in mice within two and a half hours.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Kolkata News, download Indian Express App.

The Indian Express (P) Ltd

See the original post:
Kolkata institute claims cure for Covid-19, but drug will take two years to hit market - The Indian Express

Read the Rest...

Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 – Jewish Life News

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 – Jewish Life News

The market research study titled Global Nanomedicine Market Size, Status and Forecast 2020-2026 brings you the most recent and the most updated data on the market. The report provides extensively researched information about the global Nanomedicine market structure, valuates, and outlines its variable aspects and applications. The report comprehensively represents the context of current and future trends driving the profit matrix. The report contains computable information, qualitative information sets, and evaluation tools. The research highlights major market insights, challenges, current trends, and value chain analysis.

The study provides estimates on global Nanomedicine market share, market size, and regional topography along with statistics, diagrams and charts explaining the differing interesting framework of the industry landscape. Divided by product type, applications, industry verticals, and research regions, the report research document delivers an explanation of the perspectives and comprehensive market statistics. It further covers the pricing of the product, production and consumption volume, cost analysis, industry value, barriers and growth drivers, major market players, demand and supply ratio of the market, the growth rate of the market and forecast from 2020 to 2026. Top players are completely profiled in this report.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/28942/request-sample

The major manufacturers covered in this report: Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences,

Regional Analysis For Market:

North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa) are leading countries and provide data like market share (%), sales (volume), imports & exports by types and applications, analysis, production, consumption, and consumption forecast. Information about different regions helps the reader to understand the global Nanomedicine market better.

Product type coverage (market size & forecast, a major company of product type etc.):

Application coverage (market size & forecast, different demand market by region, main consumer profile etc.): Segmentation encompasses oncology, Infectious diseases, Cardiology, Orthopedics, Other

Moreover, the report has included the leading merchants in this global Nanomedicine market everywhere throughout the world. In this part, market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue are determined. Additionally, upstream raw materials and downstream demand studies are administered. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The report further incorporates speculation attainability investigation and venture return investigation.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanomedicine-market-size-status-and-forecast-2020-2026-28942.html

Some of The Points Explained in The TOC of Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

Originally posted here:
Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 - Jewish Life News

Read the Rest...

Nanomedicine Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 – Latest Herald

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 – Latest Herald

Global Nanomedicine Market is Segmented by Application, End-Use, Product Type and Region

Global Nanomedicine Market 2020: This is a latest report, covering the current COVID-19 impact analysis on the market. This has led to several changes in market conditions. The rapidly changing market scenario as well as the first and future impact assessment are covered with in the report.

The Nanomedicine Market research report included analysis of various factors that increase market growth. It contains trends, restrictions and drivers that change the market positively or negatively. The Nanomedicine Market Report includes all key factors that affect global and regional markets, including drivers, detention, threats, challenges, risk factors, opportunities, and industry trends. This business research paper provides an in-depth assessment of all critical aspects of the global market in relation to Nanomedicine market size, market share, market growth factor, main suppliers, sales, value, volume, main regions, industry trends, product demand, capacity, cost structure and Nanomedicine market expansion. The report begins with an overview of the structure of the industry chain and describes the industry environment. Then the size of the market and the Nanomedicine forecasts are analyzed by product type, application, end use and region. The report presents the situation of competition on the market between suppliers and the profile of the company. In addition, this report analyzes the market prices and treated the characteristics of the value chain.

For Better Understanding, Download Free Sample Copy Of Nanomedicine Market Report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=LHN&utm_medium=888

Why choose us: 24/7 research support | Personalized research service 360 degree approach | 100% customer satisfaction Quality assured

The major players in the market include:

Global Nanomedicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Nanomedicine Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Nanomedicine market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Nanomedicine market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=LHN&utm_medium=888

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Nanomedicine world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Nanomedicine market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Nanomedicine world industry from 2020 to 2026 is provided to determine the potential of the Nanomedicine market.

This Nanomedicine Market Report Answers To Your Following Questions:

Who are the main global players in this Nanomedicine market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=LHN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Nanomedicine Market Size, Nanomedicine Market Trends, Nanomedicine Market Growth, Nanomedicine Market Forecast, Nanomedicine Market Analysis

Read the rest here:
Nanomedicine Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 - Latest Herald

Read the Rest...

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan…

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan…

TEL AVIV, Israel & PARSIPPANY, N.J. & INCHEON, South Korea--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that TRUXIMA (rituximab-abbs) injection is now available in the United States for the treatment of:

TRUXIMA is the only biosimilar to the reference product Rituxan1 (rituximab) available to treat rheumatoid arthritis in the United States. See important safety information below including Boxed Warning regarding fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.

We are proud to make TRUXIMA available to patients and providers as a treatment option for these indications, especially as this is the only rituximab biosimilar indicated for rheumatoid arthritis, said Brendan OGrady, Executive Vice President, North America Commercial, Teva. Following the launch of our other biosimilar earlier this year, we remain focused on our commitment to lower healthcare costs and increase price competition through the availability of biosimilars.

Celltrion Healthcare and Teva Pharmaceutical Industries Ltd. entered into an exclusive partnership in October 2016 for Teva to commercialize TRUXIMA in the U.S. and Canada. In May 2019, TRUXIMA was approved by the U.S. Food and Drug Administration (FDA) to match all of the reference products oncology indications described below.

We are pleased that patients in the United States can now have access to TRUXIMA for these new indications, said Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We believe that the continued use of biosimilars in the U.S. market will contribute to addressing unmet needs for patients and providers.

Earlier this year, the Centers for Medicare and Medicaid Services (CMS) granted pass-through status for TRUXIMA in the hospital outpatient setting. The Wholesale Acquisition Cost (WAC or list price) for TRUXIMA will be 10 percent lower than the reference product. TRUXIMA is expected to be available through primary wholesalers at a WAC of $845.55 per 100mg vial and $4,227.75 per 500mg vial. Actual costs to individual patients and providers for TRUXIMA are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patients insurance payer and eligibility for participation in the assistance program.

Teva also offers dedicated patient support services through the CORE program. CORE is available to help eligible patients, caregivers and healthcare professionals navigate the reimbursement process. CORE offers a range of services, including benefits verification and coverage determination, support for precertification and prior authorization, assistance with coverage guidelines and claims investigation, and support through the claims and appeals process. A savings program is also available for eligible commercially insured patients. To learn more, please visit TevaCORE.com.

Please see the Important Safety Information below including the Boxed Warning regarding fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. For more information, please see the full prescribing information.

Indications TRUXIMA (rituximab-abbs) is indicated for the treatment of adult patients with:

Non-Hodgkins Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Rheumatoid Arthritis (RA)

Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)

Important Safety Information

WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Infusion-Related Reactions: Administration of rituximab products, including TRUXIMA, can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue TRUXIMA infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions

Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products

Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with TRUXIMA. Discontinue TRUXIMA and concomitant medications in the event of HBV reactivation

Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions - Rituximab products can cause severe, including fatal, infusion-related reactions. Severe reactions typically occurred during the first infusion with time to onset of 30-120 minutes. Rituximab product-induced infusion-related reactions and sequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death

Premedicate patients with an antihistamine and acetaminophen prior to dosing. For RA, GPA, and MPA patients, methylprednisolone 100 mg intravenously or its equivalent is recommended 30 minutes prior to each infusion. Institute medical management (e.g. glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. Depending on the severity of the infusion-related reaction and the required interventions, temporarily or permanently discontinue TRUXIMA. Resume infusion at a minimum 50% reduction in rate after symptoms have resolved. Closely monitor the following patients: those with pre-existing cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (25,000/mm3)

Severe Mucocutaneous Reactions - Mucocutaneous reactions, some with fatal outcome, can occur in patients treated with rituximab products. These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has been variable and includes reports with onset on the first day of rituximab exposure. Discontinue TRUXIMA in patients who experience a severe mucocutaneous reaction. The safety of re-administration of rituximab products to patients with severe mucocutaneous reactions has not been determined

Hepatitis B Virus Reactivation - Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs classified as CD20-directed cytolytic antibodies, including rituximab products. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive)

HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA levels or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels. In severe cases increase in bilirubin levels, liver failure, and death can occur

Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with TRUXIMA. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during TRUXIMA treatment

Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following TRUXIMA therapy. HBV reactivation has been reported up to 24 months following completion of rituximab therapy

In patients who develop reactivation of HBV while on TRUXIMA, immediately discontinue TRUXIMA and any concomitant chemotherapy, and institute appropriate treatment. Insufficient data exist regarding the safety of resuming TRUXIMA treatment in patients who develop HBV reactivation. Resumption of TRUXIMA treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing HBV

Progressive Multifocal Leukoencephalopathy (PML) - JC virus infection resulting in PML and death can occur in rituximab product-treated patients with hematologic malignancies. The majority of patients with hematologic malignancies diagnosed with PML received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant. Most cases of PML were diagnosed within 12 months of their last infusion of rituximab

Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture

Discontinue TRUXIMA and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML

Tumor Lysis Syndrome (TLS) - Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, sometimes fatal, can occur within 12-24 hours after the first infusion of rituximab products in patients with NHL. A high number of circulating malignant cells ( 25,000/mm3) or high tumor burden, confers a greater risk of TLS

Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated

Infections - Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of rituximab product-based therapy. Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure). New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue TRUXIMA for serious infections and institute appropriate anti-infective therapy. TRUXIMA is not recommended for use in patients with severe, active infections

Cardiovascular Adverse Reactions - Cardiac adverse reactions, including ventricular fibrillation, myocardial infarction, and cardiogenic shock may occur in patients receiving rituximab products. Discontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of TRUXIMA for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina

Renal Toxicity - Severe, including fatal, renal toxicity can occur after rituximab product administration in patients with NHL. Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. The combination of cisplatin and TRUXIMA is not an approved treatment regimen. Monitor closely for signs of renal failure and discontinue TRUXIMA in patients with a rising serum creatinine or oliguria

Bowel Obstruction and Perforation - Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving rituximab in combination with chemotherapy. In postmarketing reports, the mean time to documented gastrointestinal perforation was 6 (range 1-77) days in patients with NHL. Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur

Immunization - The safety of immunization with live viral vaccines following rituximab product therapy has not been studied and vaccination with live virus vaccines is not recommended before or during treatment

Prior to initiating TRUXIMA physicians should ensure patients vaccinations and immunizations are up-to-date with guidelines. Administration of any non-live vaccines should occur at least 4 weeks prior to a course of TRUXIMA

Embryo-Fetal Toxicity - Based on human data, rituximab products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in-utero. Advise pregnant women of the risk to a fetus. Females of childbearing potential should use effective contraception while receiving TRUXIMA and for 12 months following the last dose of TRUXIMA

Concomitant Use With Other Biologic Agents and DMARDS Other Than Methotrexate

Observe patients closely for signs of infection if biologic agents and/or DMARDs are used concomitantly as limited safety data is available.

Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with rituximab products

Use in RA Patients Who Have Not Had Prior Inadequate Response to TNF Antagonists

TRUXIMA should only be used in patients who have had a prior inadequate response to one or more TNF antagonist

Most common adverse reactions in clinical trials of NHL (25%) were: infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia

Most common adverse reactions in clinical trials of CLL (25%) were: infusion-related reactions and neutropenia

Most common adverse reactions in clinical trials of RA (10%) were: upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis (other important adverse reactions include infusion-related reactions, serious infections, and cardiovascular events)

Most common adverse reactions in clinical trials of GPA and MPA (15%) were: infections, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema, and infusion-related reactions

Nursing Mothers - There are no data on the presence of rituximab in human milk, the effect on the breastfed child, or the effect on milk production. Since many drugs including antibodies are present in human milk, advise a lactating woman not to breastfeed during treatment and for at least 6 months after the last dose of TRUXIMA due to the potential for serious adverse reactions in breastfed infants

About TRUXIMA TRUXIMA (rituximab-abbs) is a U.S. Food and Drug Administration (FDA)-approved biosimilar to RITUXAN (rituximab) for the treatment of: adult patients with CD20-positive, B-cell NHL to be used as a single agent or in combination with chemotherapy or CLL in combination with fludarabine and cyclophosphamide (FC); for rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies; and granulomatosis with polyangiitis (GPA) (Wegeners Granulomatosis) and microscopic polyangiitis (MPA) in adult patients in combination with glucocorticoids

TRUXIMA has the same mechanism of action as Rituxan and has demonstrated biosimilarity to Rituxan through a totality of evidence.

About Celltrion Healthcare, Co. Ltd. Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcares products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

Teva's Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of TRUXIMA Injection for Rheumatoid Arthritis in the United States, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors and Forward Looking Statements. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1 RITUXAN is a registered trademark of Genentech and Biogen.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005064/en/

More here:
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan...

Read the Rest...

What is the 7G ERC and how could it help with COVID-19 incident? – Crestone Eagle

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on What is the 7G ERC and how could it help with COVID-19 incident? – Crestone Eagle

The 7G Emergency Restoration Coalition (7GERC) is an open-source idea born from my training and experience as a fire fighter and EMT (National Wild Fire Cordinating Group and the incident command system [ICS] FEMA. I am also incorporating the seventh generation philosophy to create this project; it came to life for me when directing the 2018 7G Crestone Energy Fair (CEF).

I extend my sincere condolences to any losses you or your loved ones may have had from this pandemic. I hope the local govenment gets something useful out of this project. The 7GERC visual aid planning wheel below is designed to quickly assist people during emergencies by showing a flow and guide for actions. Hopefully the wheel will help assist you, our community leaders, doctors, businesses, health care workers and the Community Emergency Response Team (CERT) who are helping with the COVID-19 issue. May it help our team spirit rebuild trust for our mutually beneficial, reciprocal relationships that keep us thriving in such a small town.

Planning, response and recovery

Both new and old approaches will be needed for new symbiosis within our community. In order for us best to succeed we will need to have a strong Mind (mental health and virtuous leadership), Body (physical health and local conservation/economy), and Spirit (whole love and vital unity). The ICS, 7G and zen philosophies have been baked in with permaculture principles to build out this system.

Thoughts on moving forward

The long game . . . what it could become. If we all support groups like CEF, CERT, CBR (Crestone Baca Resislience) and others to build a hall and common mission together, they/we could help give each other a hand up and restart confidence, morale and healthy community interaction. All the groups working together could help secure critical infrastructure with off-grid food, water and medicine, shelter, heating, power, and education, etc. Could it be that COVID-19 is a catalyst or paradigm shifter for renewed inspiration for back-to-the-land practices? We can share each others diversified skill sets, specifically in the cultivation of happiness, health . . . and basic living, trade, farmsteading, greenhouses, cooperative farmshares, and celebration of restoration. Symbiotically!

The short game . . . what to do now. A good way to start, Ive found, is to set personal goals. One is to become more symbiotically attuned to the new bugs in the air . . . breathe like you landed on a new planet and just had your first breath of air. Of course take logical protective measures, and ask for the probiotic bugs to be strong! Also very important is attempting ones best to understand, adapt and make peace with all relationships in life, on all levels, from the most microscopic creaturewhich is equally important to the whole human living systemto the entire known planet. The symphony that all life dances to is dependant on all cycles being in balanced harmony to create the biostasis that we have become accustomed to, and which we thrive within. Its a beautiful thing to come to terms with the reality of how much life is in our compost heaps, for exampleone handful of living soil should have millions of microscopic, helpful beings, and that is what is required to grow truly healthy food. And, learning to know that the average human has up to nine billion non-human microscopic life forms in and on us, Wow! If we are smartwe are working with them, listening to them, and learning from them to help keep COVID-19 down.

Bottom line: We all breathe the same air! If things get too complicated just count to 5! Go back to the basic fundamental science of all nourishment comes from the sun and earth. Hit the reset button! Perhaps the simplicity of chopping wood and carrying water (living close to the land) will help us remember If youre fed, warm, and loved it really doesnt get much better. Also digging in the soil and planting seeds in the rain and sunshine leads to a feeling of being a part of the web of life, and this can give purpose and meaning to the humans day.

What works for you? Going outside for the day, following a bug! Balancing with the rhythm of nature for a nourishing source of energy, finding an inner peace and confidence within the wisdom of lifes web, for you are a part of this! Shed what is no longer needed, less is more, enjoy non-action. Utilizing appropriate technology is key to this journey, and by making choices for the long haul or seven generations, preparing for the future can become simple. Without a healthy inter-woven relationship with the world our food chain and homeostasis could change before our very eyes!

Restoration . . . Our community can improve its self-stewardship with a bit of discipline and increased spirit of service. As far as sharing space with others, well, 6 will have to do for now. If you can get out of the house before going crazy, get educated by another source and dont be exploited by spooks with fear for sale. Again, the main mission is to assist efforts already in place by local groups and government, and to support one another in healthy relationships. Things that ultimately matter the mostas written by the Crestone Mountain Grange crew, Food, Family and Safety. Nourishing life from living soil and sunshine seems essential now above all else because, well, the other stuff is just revealed as rather trivial now.

It will take a village to do this work! God speed!

In service,

Nathan Good

Visit link:
What is the 7G ERC and how could it help with COVID-19 incident? - Crestone Eagle

Read the Rest...

Exactly How to Identify Chigger Bites, and Get Rid of the Annoying Berry Bugs for Good – Prevention.com

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Exactly How to Identify Chigger Bites, and Get Rid of the Annoying Berry Bugs for Good – Prevention.com

If youre a lover of the great outdoors, then you understand one nuisance all too well: There are a lot of insects to ward off. From mosquitoes to ticks, plenty of blood-sucking bugs are looking to get a taste of youand chiggers are just another pest waiting for their chance, especially in the midwest, south, and southeast parts of the U.S.

Also known as berry bugs, red bugs, and harvest mites, chiggers are so small (think: 1/120-1/150 inch) that theyre hard to see with the naked eye. But if youve ever been bitten by one, you know the itch it leaves behind can be intense and incessant.

So, whats the best way to deal with these parasites once spring hits? Here, we asked experts to break down what a chigger bite looks like, ways to treat and soothe the itch, and how to get rid of these berry bugs for good.

Chiggers are microscopic mites that are found in grassy areas, edges between lawns and forests, and on small mammals and birds, says Michael J. Raupp, Ph.D., professor of entomology at The University of Maryland and creator of Bug of the Week. They tend to prefer damp, shady habitats.

Chiggers become most active during the late spring through early fall, and love to hitchhike onto your skin when you walk through an infested area. On humans, chiggers usually move up to places around socks, tops of your pants, around the stomach and belt line, and under the bra, Raupp says. Only the teeny-tiny, larval chiggers (a.k.a. babies!) bite humans.

Chiggers do attach to and bite the skin, but contrary to popular belief, they dont burrow into your skin or suck blood. Most commonly, you can find chigger bites around the ankles, wrists, thighs, groin, and waist. While they can be extremely uncomfortable, rest assured that chiggers arent known to carry or transmit any diseases to humans.

But the mechanism behind their bite is pretty crazy. Once the mite finds its host, the chigger secretes a digestive enzyme that breaks down your skin cells, causing the skin tissue to form a hardened, raised area that functions as a feeding tube. (This tube allows the mite to gain access to the digested skin cells.) After feeding for up to three days, the mite falls off. Cue the the relentless itching, which begins roughly three to six hours after the initial bite.

Itching can last for up to two weeks, says Raupp. Its your reaction to the protein secreted into your skin, which your body breaks down over time.

In addition to the itching, you can identify a chigger bite by the way it looks. On the skin, you might see either a flat, red patch or a raised, red bump, or sometimes even blisters or pustules, says Rajani Katta, M.D., a board-certified dermatologist who serves as voluntary clinical faculty of both the Baylor College of Medicine and the McGovern Medical School, University of Texas Houston.

The good news is that these pesky bites will resolve on their own after several days. However, youll probably be dying for some relief. Here are a few different treatment options for itchy skin:

OTC topical ointments: Apply soothing over-the-counter products like menthol or calamine to reduce itch, says Joshua Zeichner, M.D., director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City.

You can also try an OTC hydrocortisone ointment to help reduce the redness and itching, says Dr. Katta. This can be used twice a day for up to two weeks to the area, although usually the symptoms will resolve before then.

OTC oral meds: For some people, taking an antihistamine by mouth, such as diphenhydramine (Benadryl), can help with the itching, although it does cause drowsiness, says Dr. Katta.

Cool compresses: This can also reduce inflammation and provide temporary relief from the itchiness, says Dr. Zeichner. Grab a frozen bag of peas if you have to. Its important to stop scratching at the skin, otherwise you may open yourself up to secondary infection.

Prescription topicals: If it gets really bad, your dermatologist can give you a prescription for a cortisone cream stronger than what is available over the counter, says Dr. Zeichner.

Skip these remedies: We dont recommend treatments such as rubbing alcohol, witch hazel, or apple cider vinegar, says Dr. Katta, as they can be irritating. Also, theres a common myth that applying nail polish to a chigger bite will work to suffocate the mites, but this doesnt hold up, as chiggers dont actually burrow into the skin, says Dr. Katta.

The best way to treat a chigger bite? Avoid getting one in the first place with these tips:

Apply insect repellant: Raupp suggests applying a DEET-based repellent on your boots and clothing if youre heading out to areas with thick greenery (avoid spraying directly onto your skin). If youre going to be out for a long amount of time, be sure to reapply your repellent ever two to three hours, Raupp says.

Wear protective clothing: If you are going to be in grassy fields, make sure to wear long pants and sleeves, says Dr. Zeichner. Wearing permethrin-treated clothing, which also works effectively against ticks, can also be helpful.

Hit the shower ASAP: Once you get back indoors, you should immediately take a hot shower and use soap to thoroughly wash your body to remove any remaining mites, says Dr. Zeichner. If you dont have access to a shower right way, use a towel to brush off your bodythis may help dislodge any that have camped out on your skin.

Throw your clothes in the wash: Take off your clothing immediately after coming indoors. You should wash your clothing in hot, soapy water to kill any mites that may be living in the seams, says Dr. Zeichner. Hot is important here, as the mites can survive a wash in a cool cycle.

If you feel like there are tons of chiggers hanging out near your home, the best thing you can do is get rid of their habitat. Mow your lawn, trim your bushes, clear out tall weeds and grasses, and generally cut back any brush. It may seem simple, but this deprives the minuscule mites of the moisture and shade theyre drawn toand also keeps other animals they like to latch onto, like rodents, away from your lawn.

Its important to do this landscaping each year as the weather starts to warm up, as adult chiggers will burrow into the soil during winter and lay eggs once spring hits, potentially infesting your yard all over again.

Support from readers like you helps us do our best work. Go here to subscribe to Prevention and get 12 FREE gifts. And sign up for our FREE newsletter here for daily health, nutrition, and fitness advice.

More here:
Exactly How to Identify Chigger Bites, and Get Rid of the Annoying Berry Bugs for Good - Prevention.com

Read the Rest...

Veterinary Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County Courier

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Veterinary Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Bandera County Courier

Verified Market Research recently published a research report titled, Veterinary Medicine Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Veterinary Medicine market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=21894&utm_source=BCC&utm_medium=002

Veterinary Medicine Market Leading Players:

Veterinary Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=21894&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Veterinary Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Veterinary Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Veterinary Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Veterinary Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Veterinary Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Veterinary Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Veterinary-Medicine-Market/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Veterinary Medicine Market Size, Veterinary Medicine Market Trends, Veterinary Medicine Market Forecast, Veterinary Medicine Market Growth, Veterinary Medicine Market Analysis

Read more:
Veterinary Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier

Read the Rest...

Global Anatomic Pathology Market : Industry Analysis and Forecast (2019-2026) – MR Invasion

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Global Anatomic Pathology Market : Industry Analysis and Forecast (2019-2026) – MR Invasion

Global Anatomic Pathology Market was valued US$ XX Bn in 2018 and is expected to reach US$ 35.70 Bn by 2026, at a CAGR of around XX % during a forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample//35844/

Global Anatomic Pathology Market

Anatomic (or anatomical) pathology is the branch of medicine that studies the effect of disease on the structure of body organs, both as a whole (grossly) and microscopically. The primary role of anatomic pathology is to identify abnormalities that can help to diagnose disease and manage treatment. Although one of the frequent uses of anatomic pathology is to help identify and manage various types of tumors or cancers, it is also valuable in evaluating other conditions, including kidney and liver diseases, autoimmune disorders, and infections, for example. In fact, in most hospitals, all tissue removed during surgery must be examined by a pathologist. Increase in clinical use of biomarkers enables pathologists to determine disease pathogenesis at a molecular level and guides in clinical decision-making, thereby improving patient outcomes. Growing reliance on biomarkers-based pathology tests and procedures to explore common malignancy and tumorigenesis are driving the market.

High usage of advanced pathology equipment such as staining systems, gross imaging, and digital microscopes is poised to improve anatomic pathological practices to a major extent. Digital imaging solutions offer specificity and accuracy-related benefits over conventional techniques, which in turn, boosts the service uptake rate in the overall market.However, the high amount of consolidation in the manufacturing is expected to act as a restraint to the market growth, stringent regulations, and problems associated with the reimbursement procedures.

The report covers all the trends and technologies playing a major role in the growth of the medical imaging workstation market during the forecast period. It highlights the drivers, restraints, and segmentation expected to influence the market growth during 2019-2026.

The instruments segment is held to dominate the xx% market share during the forecast period. Because of developing the preference for superior feature instruments that improve the surgical performances. Increasing the number of bacterial and fungal infections will surge the needs for anatomy pathological instruments so enhancing the production growth.

Disease diagnosis segment is expected as the leading segment in the anatomic pathology market during the forecast period, owing to the growing geriatric population, and an increasing number of patients suffering from chronic diseases. However, medical innovation is category is expected to witness sluggish growth, with a CAGR of XX % during the forecast period. The growing demand for diagnosing diseases has improved segmental growth.

Geographically, North America is estimated to be the largest market for vehicle security systems during the forecast period, owing to increasing investments by government & academic research centers in diagnostic research, prevalence of lung cancer & other chronic diseases, growing elderly population, the presence of major players in this region and high attention to biomarkers research.

The report covers the recent development in the anatomic pathology market like in April 2018, Thermo Fisher and Leica Microsystems collaborated for the development of an integrated cryo-tomography workflow for investigation. Under this association, the enterprises merged their existing technology to provide enhanced user-friendly and reliable microscopic solutions, enabling investigators to gain insights about biological processes.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying//35844/

The objective of the report is to present a complete calculation of the Global Anatomic Pathology Market and contains thoughtful insights, historical data, facts, industry-validated market data and plans with a suitable set of assumptions and methodology. The report also helps in the Global Anatomic Pathology Market is a dynamic structure by identifying and analyzing the market segments and project the global market size. The additional, report also focuses on the competitive analysis of key players by-product, financial position, price, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Anatomic Pathology Market.Scope of the Global Anatomic Pathology Market

Global Anatomic Pathology Market, By Product and Service

Instrumentso Tissue Processing Systemso Slide Staining Systemso Microtomeso Others Consumableso Antibodies & Reagentso Kitso Probeso Others Serviceso Cytopathologyo HistopathologyGlobal Anatomic Pathology Market, By Application

Disease Diagnosis Drug Discovery and Development OthersGlobal Anatomic Pathology Market, By End-User

Hospitals Research Laboratories Diagnostic Laboratories OthersGlobal Anatomic Pathology Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Anatomic Pathology Market

Thermo Fisher Scientific Cardinal Health F. Hoffmann-La Roche AG Agilent Technologies Quest Diagnostics Incorporated NeoGenomics Laboratories Agilent Technologies General Data Healthcare Inc. Primera Technology AP Easy Software Solutions Zebra Technologies Corporation Koninklijke Philips N.V. Leica Microsystems Laboratory Corporation of America Holdings Danaher Sakura Tech Nikon Corporation PerkinElmer Boston Scientific Corporation Advanced Cell Diagnostics Tecan Trading AG Enzo Biochem Inc.

MAJOR TOC OF THE REPORT

Chapter One: Anatomic Pathology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Anatomic Pathology Market Competition, by Players

Chapter Four: Global Anatomic Pathology Market Size by Regions

Chapter Five: North America Anatomic Pathology Revenue by Countries

Chapter Six: Europe Anatomic Pathology Revenue by Countries

Chapter Seven: Asia-Pacific Anatomic Pathology Revenue by Countries

Chapter Eight: South America Anatomic Pathology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Anatomic Pathology by Countries

Chapter Ten: Global Anatomic Pathology Market Segment by Type

Chapter Eleven: Global Anatomic Pathology Market Segment by Application

Chapter Twelve: Global Anatomic Pathology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Anatomic Pathology Market Report at: https://www.maximizemarketresearch.com/market-report/global-anatomic-pathology-market/35844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read more from the original source:
Global Anatomic Pathology Market : Industry Analysis and Forecast (2019-2026) - MR Invasion

Read the Rest...

Coronavirus threat to global Spinal Muscular Atrophy Medicine Market : Trends and Future Applications – Latest Herald

§ May 4th, 2020 § Filed under Nano Medicine Comments Off on Coronavirus threat to global Spinal Muscular Atrophy Medicine Market : Trends and Future Applications – Latest Herald

The novel Coronavirus (COVID-19) has caused a slowdown in the global economy and disrupted the stock markets. Hence, companies in the Spinal Muscular Atrophy Medicine market are tapping incremental opportunities via alternative business solutions to revive market growth post the lockdown period. Get a full analysis report on the impact of Coronavirus which has affected the Spinal Muscular Atrophy Medicine market and learn how businesses are tackling the situation.

Assessment of the Global Spinal Muscular Atrophy Medicine Market

According to the latest report on the Spinal Muscular Atrophy Medicine market, the market is expected to reach a value of ~US$XX by 20XX and register a CAGR growth of ~XX% during the forecast period (20XX-20XX). The report provides a thorough understanding of the various factors that are expected to influence the current and future prospects of the Spinal Muscular Atrophy Medicine market including the major trends, growth opportunities, restraints, and drivers.

The SWOT and Porters Five Forces Analysis by analysts of ResearchMoz.us offers a fair idea of the operations of some of the key players operating in the Spinal Muscular Atrophy Medicine market. The current structure of the market and the estimated growth of the market over the forecast period is accurately represented in the report along with graphs, figures, and tables.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2633762&source=atm

Segregation of the Spinal Muscular Atrophy Medicine Market:

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by Type, the Spinal Muscular Atrophy Medicine market is segmented intoLMI-070ND-602NT-1654NusinersenNXD-30001Others

Segment by ApplicationHospitalClinicOthers

Global Spinal Muscular Atrophy Medicine Market: Regional AnalysisThe Spinal Muscular Atrophy Medicine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Spinal Muscular Atrophy Medicine market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.EGlobal Spinal Muscular Atrophy Medicine Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.The major players in global Spinal Muscular Atrophy Medicine market include:Astellas Pharma Inc.AveXis, Inc.Bioblast Pharma Ltd.Cytokinetics, Inc. 24F. Hoffmann-La Roche Ltd.GenethonGenzyme CorporationGMP-Orphan SASIonis Pharmaceuticals, Inc.Longevity Biotech, IncNeurodyn Inc.Neurotune AGNovartis AGSarepta Therapeutics, Inc.Voyager Therapeutics, Inc.Vybion, Inc.WAVE Life Sciences Ltd.

The report includes a Y-o-Y growth assessment of each of these market segments and sub-segments. Further, the market share, size, revenue growth, and CAGR growth of each segment is accurately presented in the in-depth study of the Spinal Muscular Atrophy Medicine market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2633762&source=atm

Valuable Insights Enclosed in the Report

The presented study resolves the following doubts related to the Spinal Muscular Atrophy Medicine market:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2633762&licType=S&source=atm

Read the original post:
Coronavirus threat to global Spinal Muscular Atrophy Medicine Market : Trends and Future Applications - Latest Herald

Read the Rest...

Mad about the Girl: has science solved the riddle of Vermeer’s masterpiece? – Telegraph.co.uk

§ May 3rd, 2020 § Filed under Nano Medicine Comments Off on Mad about the Girl: has science solved the riddle of Vermeer’s masterpiece? – Telegraph.co.uk

One unexpected joy of lockdown has been the trend on social media to share witty, home-grown recreations of famous paintings. After the Getty in LA last month urged followers online to mock up favourite artworks using three things lying around the house, the challenge quickly spread, and the results have grown ever more ingenious. In one post, an olive sleeping bag evokes the green dress in Van Eycks Arnolfini Portrait. Tangled charging cables summon Caravaggios snake-haired Medusa. A yellow labrador, in a third, calls to mind Ingress Grande Odalisque.

The subset of the genre I most cherish, though, involves photographs of food: a sliced red pepper that resembles The Scream; a plate of folded ham that perfectly captures The Persistence of Memory. And, most brilliantly of all, a humble, sprouting brown onion that, embellished with a blue strap, and carefully lit against a dark background, conjures Johannes Vermeers Girl with a Pearl Earring.

Unsurprisingly, the 17th-century Dutch masters oil painting the inspiration for the bestselling historical novel by Tracy Chevalier adapted, in 2003, into a film starring Scarlett Johansson has found an afterlife on the internet. As well as being obviously gorgeous, Girl with a Pearl Earring is also thrillingly modern. A young woman wearing a blue-and-yellow headscarf swivels her head to the left while parting moist lips as though about to speak.

And thats kind of it. On paper, not much. Yet, somehow, Vermeer captures a moment of intimacy and spontaneity with great intensity. Whoever this figure is, her presence, her psychology, feels palpable. Moreover, while many of Vermeers contemporaries would have placed her in a highly realistic setting, he offers something different: radiant, yet stripped back. And, thus, seemingly timeless. Its hard to place this girl, which is why its still so easy to identify with her. Plus, of course, shes highly reproducible. Which makes this the perfect Old Master painting for the digital age. Even Banksy has paid homage to Girl with a Pearl Earring, in a mural in Bristol that was recently updated with a surgical mask.

Last week, Vermeers painting sparked headlines again, following the announcement, at a virtual press conference organised by the Mauritshuis in The Hague, of the findings of a painstaking investigation into the picture by an international team of scientists.

A couple of years ago, I travelled to the Mauritshuis, where the work hangs, to report on a crucial phase of the project for the BBC. Vermeers Girlhad been taken off the wall, removed from her frame, and carefullypositioned, in public view behind glass, in a temporary laboratory set up within the museums opulent 17thcentury Golden Room.

The 1665 painting then received the art-historical equivalent of a full-body scan, as experts analysed it using 21st-century technology, including digital microscopy. At the time, Emilie Gordenker, then the director of the Mauritshuis, compared the approach to medical research. Indeed, some of the scientific techniques were borrowed directly from medicine. For instance, to study Vermeers translucent glazes, the team employed a non-invasive imaging technique called optical coherence tomography, which, as paintings conservator and head researcher Abbie Vandivere told me recently, is used to examine thin layers in the human eye.

After two weeks, Vandivere says, they had amassed nine terabytes of data, which it took many months to sift through. Paint was analysed, findings debated, until eventually it all came together in a diagnosis, revealed last week.

What, then, have we learnt? For one thing, it turns out that the Girl originally had eyelashes, which people thought Vermeer had omitted. (Curiously, though, he didnt give her eyebrows.) For another, the artists signature, so hard to see in the upper left-hand corner, was confirmed: by mapping the different chemical elements, Vandivere explains, researchers could visualise very precisely the layout of [Vermeers] monogram: IVMeer. And we now understand the order in which Vermeer painted the picture, as well as changes he made along the way.

See original here:
Mad about the Girl: has science solved the riddle of Vermeer's masterpiece? - Telegraph.co.uk

Read the Rest...

Column: Is this the end of the innocence? – Milford Daily News

§ May 3rd, 2020 § Filed under Nano Medicine Comments Off on Column: Is this the end of the innocence? – Milford Daily News

I awoke last night at 3 a.m. with the metallic taste of fear in my mouth.

Columns share an author's personal perspective and are often based on facts in the newspaper's reporting.

Something from the future is peeking out and its just too big for our minds

From "Chernobyl Prayer" by Svetlana Alexievich

I awoke last night at 3 a.m. with the metallic taste of fear in my mouth. I felt a deep sense of despair and alarming uncertainty. Perhaps this is the feeling that an American soldier may have had during the Vietnam war as he slept with his platoon in the jungles of Southeast Asia. The enemy is out there in the dark, maintaining radio silence, laying low, motionless, but definitely there and waiting.

Perhaps the crack of a branch or the screech of a monkey spiked massive amounts of adrenaline into his bloodstream.

Our COVID-19 enemy is millionths of an inch in size yet equally as deadly as any army. When this brave new world of COVID-19 began I was not a believer. I rationalized that this was yet another of the many minor incidents aggrandized and politicized by the media. I was a prisoner of illusion. Now I have egg on my face, more accurately the entire omelet!

COVID-19 is not some fever dream that we will suddenly awake from. It is a full-scale global Chernobyl - a meltdown of biology on an epic scale. The saying goes You dont know what youve got till its gone. We are getting a dose of this nasty medicine now with more to come, and it is not something that we here in the land of plenty like or are accustomed to. Will it get worse? Better? Opinions vary, but the experts cannot say for certain. Perhaps it is this uncertainty and lack of consensus that is most disturbing.

I have been a follower of ecological and environmental sciences for five decades. Like so many of us I watched helplessly as the planet grew warmer, fish and wildlife stocks declined, air and water quality spiraled downward, and we buried ourselves under mountains of plastic refuse.

Twenty years ago, I attended a conference at MIT where the best minds on the planet in all fields of earth sciences convened to share their knowledge and wisdom. The consensus amongst the best and brightest from all corners of the globe was that our planet had an infinitely sustainable capacity (the ability to regenerate resources without depletion) of between 2.2 and 2.5 billion inhabitants. We have now surpassed the upper end of this number by 300%!

I remember the 1958 groundbreaking and highly controversial Behavioral Sink experiments of ethologist John B. Calhoun. In this simple experiment rodents were placed in a fixed-size, predator-free environment with unlimited food and water. As the population was incrementally increased, harmony existed up to a point, after which stress, aggressiveness, hostility, violence, and even cannibalism became the norm until the population returned to what was sustainable, based on the size and resources of the environment.

This appears not unlike the infinitely sustainable capacity discussed at the MIT symposium. There is a point where changes of degree become changes of kind, after which chaos occurs until the population returns to what the environment can support. Calhoun indicated that he saw the Behavioral Sink outcome as the potential fate for mankind. I believe we have reached our population capacity on Earth. This upward growth curve is simply no longer sustainable.

A few years ago, I visited one of our national parks on an island along the Maryland/Virginia Border where wild horses were allowed to roam free. Although the herd size is regularly counted, there is no veterinary intervention when an animal is starving, sick or injured. In my discussion with the ranger I learned that the population never varies more than a few percent. When it goes below a certain number more horses are born and survive. When it exceeds this upper number, animals die off as a result of disease, infant mortality, starvation, or predation.

I found this tight range to be amazing considering how rapidly the population of humans has and is expanding. When I asked the ranger why this is, he remarked, That is the range that the resources (space, food, water, etc.) can support. Mother nature knew what was best for the wild horse society as a whole. Is she bestowing her wisdom upon our crowded world now? Have we reached the global population tipping point?

As the highest order creatures on the planet we have the advantage of large brains and have harnessed the ability to intervene in our own behavioral sink called planet earth. We have extended life spans, lowered infant mortality rates, cured many deadly diseases, and used pharmacology and immunology to keep illness and death at bay.

Although humans have inhabited the earth for 300,000 years, disease, plagues, high infant mortality rates, shorter life spans, famines, and even mild infections and yes, viruses, have kept our numbers relatively small. With the understanding of microbiology and the resulting miracle drugs of the 1950s such as penicillin and its derivatives, everything radically changed. The population of earth in 1950 was approximately 2.5 billion. Today it is 7.8 billion, having more than tripled.

But is there not the same amount of water, land, and resources? Technology and innovation are not illimitable. Antibiotics are marvelous weapons, up to a point. Cattle in feed lots receive large doses of antibiotics as it is well known that high animal density leads to disease. The situation is identical for factory raised poultry and farm raised fish. There is however a limit to what can be sustained, and a small step over the line can lead to an unimaginable disaster.

As for COVID-19, has nature thrown us a pitch that we are yet unable to hit? Has mother natures wisdom intervened? Has she lost her patience with our furtive and unsuccessful efforts to keep our environment sustainable and healthy? She knows that all of these ecological issues stem from overpopulation. It is clearly the only part of the equation that is not fixed. Is the herd being thinned out for the better of the balance of the population? Are we witnessing natural selection?

I have never been afraid in my life, until now. This enemy is microscopic and cannot be seen, felt, smelled, heard, or tasted. It is an equal opportunity employer and very democratic in its choice of victims. It does not care about race, religion, political leanings, sexual orientation or financial or social status. Contact with a single microbe or a billion can produce the same deadly outcome.

Is it on the doorknob? Is it safe to touch the melon at the supermarket? What about the mail?

When I look out my window I see a scene of masked zombies from Rod Serlings "Twilight Zone," and when I do my daily walk later today I will become part of the cast. I am an involuntary bit player in what will be the largest medical and sociological experiment of my lifetime.

Am I over-reacting?

In Central America I once watched as a small number of tiny leaf-cutter ants multiplied into a river of millions and devastated an entire forest. I cannot get that image out of my mind. Will we all sing in the sunshine as the white knight of medical science rides in to save the day? Or is this the end of the innocence?

Howard Axelrod is an Ashland-based travel writer and photographer who has visited 85 countries on six continents.

View original post here:
Column: Is this the end of the innocence? - Milford Daily News

Read the Rest...

Impact of COVID-19 Outbreak on Sports Medicine Devices to Garner Brimming Revenues by 2019-2026 Cole Reports – Cole of Duty

§ May 3rd, 2020 § Filed under Nano Medicine Comments Off on Impact of COVID-19 Outbreak on Sports Medicine Devices to Garner Brimming Revenues by 2019-2026 Cole Reports – Cole of Duty

Global Sports Medicine Devices Market Analysis

The recent report presented by MRRSE on the global Sports Medicine Devices market is an in-depth analysis of the overall prospects of the Sports Medicine Devices market in the upcoming years. The data collected from credible primary and secondary sources is accurately represented in the report backed up by relevant figures, graphs, and tables. The market study covers the impact of the COVID-19 pandemic on the growth prospects of the global Sports Medicine Devices market. The report includes a quantitative and qualitative analysis of the various aspects of the market by collecting data from the key participants in the Sports Medicine Devices market value chain.

The report reveals that the global Sports Medicine Devices market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and surpass the value of ~US$XX by the end of 2029. The presented study also includes a thorough analysis of the micro and macroeconomic factors, regulatory framework, and current trends that are expected to influence the growth of the Sports Medicine Devices market during the assessment period.

Request Sample Report @https://www.mrrse.com/sample/3189?source=atm

Vital Information Enclosed in the Sports Medicine Devices Market Report:

Important Queries Addressed in the Report

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/3189?source=atm

Sports Medicine Devices Market Segmentation

The market study put forward by MRRSE segments the global Sports Medicine Devices market to offer a microscopic understanding of the various aspects of the Sports Medicine Devices market. The Sports Medicine Devices market is segmented on the basis of region, product type, end-user, and more.

The study offers a Y-o-Y growth projection of each market segment and sub-segment over the stipulated timeframe of the study.

Some of the major players in sports medicine devices profiled in this report include Arthrex, Arthrocare, Biomet, Inc., Stryker Corporation, Wright Medical Technology, Inc., DJO Global, OttoBock Healthcare GmbH, Ossur hf and Zimmer Holdings, Inc. Each of these market players are profiled in this report considering parameters such as company overview, financial overview, business strategies, product portfolio and recent developments.

Read more here:
Impact of COVID-19 Outbreak on Sports Medicine Devices to Garner Brimming Revenues by 2019-2026 Cole Reports - Cole of Duty

Read the Rest...

Impact of COVID-19 Outbreak on Seasickness Medicine Market Forecast and Competitive Analysis – Jewish Life News

§ May 3rd, 2020 § Filed under Nano Medicine Comments Off on Impact of COVID-19 Outbreak on Seasickness Medicine Market Forecast and Competitive Analysis – Jewish Life News

Global Seasickness Medicine Market Growth Projection

The new report on the global Seasickness Medicine market is an extensive study on the overall prospects of the Seasickness Medicine market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Seasickness Medicine market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Seasickness Medicine market in the upcoming years and the impact of the COVID-19 pandemic on the Seasickness Medicine . In addition, the report offers valuable insights pertaining to the supply chain challenges market players are likely to face in the upcoming months and solutions to tackle the same.

The report suggests that the global Seasickness Medicine market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Seasickness Medicine market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Seasickness Medicine market over the considered assessment period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2636026&source=atm

The report clarifies the following doubts related to the Seasickness Medicine market:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2636026&source=atm

Segmentation of the Seasickness Medicine Market

Market Segment AnalysisThe research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Seasickness Medicine market is segmented intoAnticholinergicAntihistaminesOthers

Segment by ApplicationAdultsChildren

Global Seasickness Medicine Market: Regional AnalysisThe Seasickness Medicine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.The key regions covered in the Seasickness Medicine market report are:North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalyRussiaAsia-PacificChinaJapanSouth KoreaIndiaAustraliaTaiwanIndonesiaThailandMalaysiaPhilippinesVietnamLatin AmericaMexicoBrazilArgentinaMiddle East & AfricaTurkeySaudi ArabiaU.A.E

Global Seasickness Medicine Market: Competitive AnalysisThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Seasickness Medicine market include:GlaxoSmithKlinePrestige BrandsWellSpring Pharmaceutical CorporationBaxter InternationalMylanSandozPfizerMyungmoon Pharm

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2636026&licType=S&source=atm

Vital Information Enclosed in the Report

Continue reading here:
Impact of COVID-19 Outbreak on Seasickness Medicine Market Forecast and Competitive Analysis - Jewish Life News

Read the Rest...

« Older Entries Newer Entries »



Page 12«..11121314..2030..»